SBIO: A Tactical Long on Biotech Exposure as Clinical Readouts and M&A Tailwinds Align
SBIO offers concentrated exposure to small-cap biotech names in Phase II/III trials. The ETF's recovery from a 52-week low, a modest yield, and a shallow float create an attractive asymmetric trade. I recommend a long with a clear entry, stop and target over a 180 trading-day horizon while respecting heightened volatility and shorting activity.